TXNDC17

Across TCGA pan-cancer cohorts, TXNDC17 RNA differs between tumor and matched normal tissue in 16 of 18 cancer types tested, making tumor–normal expression one of TXNDC17’s most consistent transcriptional readouts.

The strongest signal is observed in lung adenocarcinoma (LUAD), where TXNDC17 RNA is more highly expressed in tumor relative to normal tissue. In most cancer types TXNDC17 is over-expressed in tumor, although a few such as KICH and COAD show the opposite, repressed pattern.

LUAD, KIRC, and KICH are the cancer types where TXNDC17 tumor–normal differential expression is most reproducible.

RNA tumor vs normal associations by lineage

Ranked by sampling consensus. Fold-change is the tumor-versus-normal difference in TXNDC17 RNA (log₂); positive values indicate higher expression in tumor. p-values are from the differential-expression test.

Lineage	Gender	Stage	Fold-change	p	Sampling consensus
LUAD	Female	III,IV	+1.719	<.001	9	view →
KIRC	All	II,III,IV	+0.313	<.001	8	view →
KICH	Female	II,III,IV	−1.057	<.001	7	view →
BLCA	All	All	+0.696	.028	7	view →
LIHC	All	II,III,IV	+0.616	<.001	7	view →
HNSC	All	All	+0.527	.003	7	view →
UCEC	All	III,IV	+1.551	<.001	6	view →
LUSC	Female	II,III,IV	+1.062	<.001	6	view →
BRCA	All	III,IV	+0.888	<.001	6	view →
CHOL	Male	All	+1.588	<.001	5	view →
PAAD	All	All	+0.650	.011	4	view →
THCA	All	All	+0.224	.003	4	view →

Pink = over-expressed in tumor, green = repressed in tumor. Showing the 12 strongest of 16 lineages.

TXNDC17–LUAD

Open the LUAD breakdown →